《肿瘤瞭望》于2014年初创刊,由著名肿瘤科专家徐兵河教授担任总编辑,以“同步传真国际肿瘤进展”为办刊宗旨,以循证医学理念为指导思想,采用全媒体组合报道模式,致力于为国内广大肿瘤临床、教研人员搭建一座与国际接轨的桥梁。 |
|
小叮读报 · 建了个书法交流群,40岁以上中老年免费学隶书 ... · 昨天 |
编者按
第66届美国血液学会(ASH)将于2024年12月7~10日在美国圣迭戈(San Diego)盛大召开。作为全球血液学领域规模最大、涵盖最全面的国际学术盛会之一,每年吸引着成千上万名来自世界各地的专家学者,分享最前沿的血液学进展和突破性临床数据。日前,大会官网公布了入选摘要,引人瞩目的是,70+篇由中国学者主导的研究入选口头报告(Oral),创历史新高!这些研究成果不仅是血液学领域探索的最前沿标志,更彰显了中国在血液学研究版图上的坚实步伐与卓越贡献。本刊特此精心整理,带您领略中国血液学专家的非凡风采与卓越成就。
恶性血液肿瘤篇
PART.01
01
摘要号:38
标题:The TFG-ROS1 Fusion Is an Oncogenic Driver of Human Myeloid Leukemia
中文标题:TFG-ROS1融合是人类髓系白血病的一个致癌驱动因素
汇报人:Jie Sun(浙江大学医学院附属第一医院骨髓移植中心)
汇报时间:Saturday, December 7, 2024: 9:45 AM
汇报地点:Room 6A (San Diego Convention Center)
02
摘要号:89
标题:Targeted-Delivery Strategy of Engineered EV Functionalized By Anti-CD3/CD19 Bi-Specific T-Cell Engager in Treating B-Cell Malignancies
中文标题:抗CD3/CD19双特异性T细胞衔接器功能化EV治疗B细胞恶性肿瘤的靶向递送策略
汇报人:Xiuiu Yang(华中科技大学同济医学院同济医院血液科)
汇报时间:Saturday, December 7, 2024: 10:30 AM
汇报地点:Ballroom 20AB (San Diego Convention Center)
03
摘要号:91
标题:Rituximab, Lenalidomide, and Zanubrutinib (ZR2) with Sequential CAR-T Cell As First-Line Therapy for High-Risk Large B Cell Lymphoma
中文标题:利妥昔单抗联合来那度胺和泽布替尼(ZR2)序贯CAR-T细胞疗法作为高危大B细胞淋巴瘤的一线治疗
汇报人:Mingming Zhang(浙江大学医学院附属第一医院骨髓移植中心)
汇报时间:Saturday, December 7, 2024: 9:30 AM
汇报地点:Marriott Grand Ballroom 11-13(Marriott Marquis San Diego Marina)
04
摘要号:92
标题:IL-10 Expressing CD19 CAR-T Cells Induce Complete Remission and Improve Long-Term Protection in Relapsed or Refractory B-Cell Hematological Malignancies
中文标题:表达IL-10的CD19 CAR-T细胞诱导复发或难治性B细胞血液恶性肿瘤完全缓解并改善长期保护作用
汇报人:Jingjing Ren(深圳市莱芒生物科技有限公司)
汇报时间:Saturday, December 7, 2024: 9:45 AM
汇报地点:Marriott Grand Ballroom 11-13 (Marriott Marquis San Diego Marina)
05
摘要号:156
标题:Potent in Vitro and In Vivo Efficacy of Hdz-C123A, a GSPT1 Degrader-Antibody Conjugate Targeting CD123 in Acute Myeloid Leukemia
中文标题:靶向CD123的GSPT1降解抗体偶联物Hdz-C123A在急性髓系白血病中的体外和体内疗效
汇报人:Yu Guo(杭州和正医药有限公司)
汇报时间:Saturday, December 7, 2024: 1:15 PM
汇报地点:Room 33 (San Diego Convention Center)
06
摘要号:222
标题:Prospective Study of Avapritinib in Patients with Relapsed/Refractory or MRD-Positive Core-Binding Factor Acute Myeloid Leukemia with KIT Mutations
汇报人:Xueqing Dou(苏州大学附属第一医院)
汇报时间:Saturday, December 7, 2024: 3:15 PM
汇报地点:Seaport Ballroom EFGH (Manchester Grand Hyatt San Diego)
07
摘要号:270
标题:Safety and Efficacy of VA Combined with Modified BuCy Conditioning Regimen Followed By Allo-HSCT for High-Risk or Refractory/Relapsed Acute Lymphoblastic Leukemia : A Prospective, Single-Center, Single-Arm Clinical Trial
中文标题:VA联合改良BuCy预处理方案后行异基因造血干细胞移植治疗高危或难治/复发急性淋巴细胞白血病的安全性和有效性:一项前瞻性、单中心、单臂临床试验
汇报人:Xiaoqian Chen(苏州大学附属第一医院)
汇报时间:Saturday, December 7, 2024: 3:15 PM
汇报地点:Room 6CF(San Diego Convention Center)
08
摘要号:312
标题:Efficacy and Safety of Adding Blinatumomab to First-Line Treatment for Chinese Children with B-Cell Acute Lymphoblastic Leukemia
中文标题:中国儿童B细胞急性淋巴细胞白血病一线治疗中加用布林妥莫单抗的疗效和安全性
汇报人:Ruidong Zhang(首都医科大学附属北京儿童医院血液学中心)
汇报时间:Saturday, December 7, 2024: 5:15 PM
汇报地点:Marriott Grand Ballroom 5-6 (Marriott Marquis San Diego Marina
09
摘要号:328
标题:Integrative Multi-Omics Analyses Identify a High-Risk Subgroup of Patients with Poor Prognosis in t(8;21) Acute Myeloid Leukemia
中文标题:综合多组学分析鉴定出t(8;21)急性髓系白血病中预后不良的高危亚组
汇报人:Yu Liu [中国医学科学院血液病医院(中国医学科学院血液学研究所)]
汇报时间:Saturday, December 7, 2024: 4:45 PM
汇报地点:Seaport Ballroom ABCD (Manchester Grand Hyatt San Diego)
10
摘要号:345
中文标题:线粒体转录翻译冲突导致剪接因子突变型骨髓增生异常综合征的红细胞生成缺陷和疾病进展
汇报人:Qiaoli Li [中国医学科学院血液病医院(中国医学科学院血液学研究所)]
汇报时间:Saturday, December 7, 2024: 4:30 PM
汇报地点:Ballroom 20CD (San Diego Convention Center)
11
摘要号:372
标题:Modified Dual CLL1-CD15 and CLL1-CD16 Icar-T Cells for Mitigating Granulocytopenia Toxicities in the Treatment of Acute Myeloid Leukemia
中文标题:改良型双靶点CLL1-CD15和CLL1-CD16 Icar-T细胞用于减轻急性髓系白血病治疗中的粒细胞减少毒性
汇报人:Rui Zhang(天津市第一中心医院)
汇报时间:Saturday, December 7, 2024: 5:15 PM
汇报地点:Grand Hall C(Manchester Grand Hyatt San Diego)
12
摘要号:452
标题:Spatial Architecture of Immune Microenvironment Orchestrating Anti-Lymphoma Immunity and the Response to Immunochemotherapy in EBV+ Diffused Large B Cell Lymphoma Revealed By Imaging Mass Cytometry and Spatial
中文标题:通过成像质谱流式细胞术和空间转录组揭示EBV+弥漫性大B细胞淋巴瘤中调控抗淋巴瘤免疫和免疫化疗反应的免疫微环境空间结构
汇报人:Zhijuan Lin(厦门大学附属第一医院血液科)
汇报时间:Sunday, December 8, 2024: 9:45 AM
汇报地点:Marriott Grand Ballroom 5-6 (Marriott Marquis San Diego Marina)
13
摘要号:477
标题:Safety and Efficacy of Tgrx-678, a Potent BCR::ABL1 allosteric Inhibitor, in Patients with Tyrosine Kinase Inhibitor Resistant and/or Intolerant Chronic Myeloid Leukemia: Updated Results of Phase 1 Study Tgrx-678 -1001
中文标题:强效BCR::ABL1变构抑制剂Tgrx-678在治疗酪氨酸激酶抑制剂耐药和/或不耐受慢性髓系白血病患者中的安全性和有效性:I期研究Tgrx-678-1001的更新结果
汇报人:江倩(北京大学人民医院)
汇报时间:Sunday, December 8, 2024: 10:00 AM
汇报地点:Harbor Ballroom DEFG (Manchester Grand Hyatt San Diego)
14
摘要号:480
标题:Olverembatinib As Second-Line (2L) Therapy in Patients (pts) with Chronic Phase-Chronic Myeloid Leukemia (CP-CML)
中文标题:奥瑞巴替尼作为慢性期慢性髓系白血病(CP-CML)患者二线(2L)治疗药物
汇报人:Weiming
Li
(华中科技大学同济医学院附属协和医院血液科)
汇报时间:Sunday, December 8, 2024: 10:45 AM
汇报地点:Harbor Ballroom DEFG (Manchester Grand Hyatt San Diego)
15
摘要号:484
标题:Rovadicitinib in Patients with Myelofibrosis Who Were Refractory or Relapsed or Intolerant to Ruxolitinib: A Single Arm, Multicenter, Open-Label, Phase Ib Study
中文标题:Rovadicitinib治疗难治、复发性或对Ruxolitinib不耐受的骨髓纤维化患者:一项单臂、多中心、开放标签、Ib期研究
汇报人:常春康(上海交通大学医学院上海第六人民医院血液科)
汇报时间:Sunday, December 8, 2024: 10:15 AM
汇报地点:Grand Hall C (Manchester Grand Hyatt San Diego)
16
摘要号:486
标题:First-in-Human Phase I/IIa Safety and Efficacy of Flonoltinib Maleate, a New Generation of JAK2/FLT3 Inhibitor in Myelofibrosis
中文标题:新一代JAK2/FLT3抑制剂马来酸氟诺替尼治疗骨髓纤维化的首个人体I/IIa期安全性和有效性研究
汇报人:Lijuan Chen(四川大学华西医院血液科)
汇报时间:Sunday, December 8, 2024: 10:45 AM
汇报地点:Grand Hall C (Manchester Grand Hyatt San Diego)
17
摘要号:576
标题:Clinical Implications of CSF-Ctdna Positivity in Newly Diagnosed Diffuse Large B Cell Lymphoma in a Large Cohort
中文标题:大型队列中新诊断的弥漫性大B细胞淋巴瘤患者脑脊液循环肿瘤DNA(CSF-ctDNA)阳性的临床意义
汇报人:梁金花 [南京医科大学第一附属医院(江苏省人民医院)血液科]
汇报时间:Sunday, December 8, 2024: 1:15 PM
汇报地点:Marriott Grand Ballroom 5-6 (Marriott Marquis San Diego Marina)
18
摘要号:599
标题:Myeloablative Allogeneic Hematopoietic Stem Cell Transplantation Improved Prognosis for Advanced NK/T Cell Lymphoma
中文标题:清髓性异基因造血干细胞移植可改善晚期NK/T细胞淋巴瘤患者的预后
汇报人:李智慧(北京高博博仁医院移植科)
汇报时间:Sunday, December 8, 2024: 1:00 PM
汇报地点:Room 11 (San Diego Convention Center)
19
摘要号:663
标题:Decitabine Plus All-Trans Retinoic Acid Versus Decitabine Monotherapy for Myelodysplastic Syndromes with Excess Blasts: A Multicentre, Randomized Controlled TrialClinically Relevant Abstract
中文标题:地西他滨联合全反式维甲酸对比地西他滨单药治疗伴有过多原始细胞的骨髓增生异常综合征:一项多中心随机对照试验
汇报人:佟红艳(浙江大学医学院附属第一医院血液科)
汇报时间:Sunday, December 8, 2024: 5:00 PM
汇报地点:Harbor Ballroom DEFG (Manchester Grand Hyatt San Diego)
20
摘要号:681
标题:Safety and Efficacy of Bicistronic CD19/CD22 CAR T Cell Therapy in Childhood B Cell Acute Lymphoblastic Leukemia
中文标题:双顺反子CD19/CD22 CAR T细胞疗法在儿童B细胞急性淋巴细胞白血病中的安全性和有效性
汇报人:Hua Zhang [SPH生物治疗(上海)有限公司]
汇报时间:Sunday, December 8, 2024: 5:00 PM
汇报地点:Marriott Grand Ballroom 2-4 (Marriott Marquis San Diego Marina)
21
摘要号:696
标题:Haploidentical Peripheral Blood Stem Cell Combined with Bone Marrow or Unrelated Cord Blood As Grafts for Acute Leukemia/Myelodysplastic Syndrome: An Open-Label, Multicenter, Randomized, Phase 3 Trial
中文标题:单倍体相合外周血干细胞联合骨髓或无关脐带血作为急性白血病/骨髓增生异常综合征移植供体的开放标签、多中心、随机、III期试验
汇报人:Sijian Yu(南方医科大学南方医院)
汇报时间:Sunday, December 8, 2024: 5:45 PM
汇报地点:Room 6A (San Diego Convention Center)
22
摘要号:832
标题:TENT5C As a Target of Chromatin Remodeler SMARCA2 Participates BTK Inhibitor Resistance in Mantle Cell Lymphoma By Regulating ATP Metabolism
中文标题:TENT5C作为染色质重塑剂SMARCA2的靶点,通过调节ATP代谢参与套细胞淋巴瘤对BTK抑制剂的耐药
汇报人:Yuting Yan [中国医学科学院血液病医院(中国医学科学院血液学研究所)]
汇报时间:Monday, December 9, 2024: 3:30 PM
汇报地点:Ballroom 20CD (San Diego Convention Center)
23
摘要号:833
标题:ST6GALNAC4 Promotes Diffuse Large B-Cell Lymphoma Progression Via Mediating Sialylation of Bmpr-1B at Thr24m
中文标题:ST6GALNAC4通过介导BMPR-1B第24位苏氨酸的唾液酸化促进弥漫性大B细胞淋巴瘤进展
汇报人:Yu Zhang(山东第一医科大学附属山东省医院血液科)
汇报时间:Monday, December 9, 2024: 3:45 PM
汇报地点:Ballroom 20CD (San Diego Convention Center)
24
摘要号:836
标题:Venetoclax Combined with Hag Regimen in Newly Diagnosed ETP-ALL: A Prospective, Multicenter, Phase 2 Trial
中文标题:维奈托克联合HAG方案治疗新诊断的早期前体T细胞急性淋巴细胞白血病:一项前瞻性、多中心、II期试验
汇报人:Shanshan Suo(浙江大学医学院附属第一医院血液科)
汇报时间:Monday, December 9, 2024: 3:00 PM
汇报地点:Marriott Grand Ballroom 2-4 (Marriott Marquis San Diego Marina)
25
摘要号:839
标题:Tucidinostat Plus Pediatric-Inspired Chemotherapy As First-Line Therapy for Newly Diagnosed ETP-ALL/Lbl: An Open-Label, Single-Arm, Phase 2 Trial
中文标题:Tucidinostat联合儿童启发化疗作为新诊断的早期前体T细胞急性淋巴细胞白血病/淋巴母细胞淋巴瘤的一线治疗:一项开放标签、单臂、II期试验
汇报人:Jieping Lin(南方医科大学南方医院血液科)
汇报时间:Monday, December 9, 2024: 3:45 PM
汇报地点:Marriott Grand Ballroom 2-4 (Marriott Marquis San Diego Marina)
26
摘要号:843
标题:The Mutated of KRAS gene Determine the Fate of KMT2A-Rearranged AML Patients
中文标题:KRAS基因突变决定KMT2A重排急性髓系白血病患者的命运
汇报人:吴一波(浙江大学医学院附属第一医院骨髓移植中心)
汇报时间:Monday, December 9, 2024: 3:15 PM
汇报地点:Grand Hall C (Manchester Grand Hyatt San Diego)
27
摘要号:874
标题:CD38 Overexpressed Monocytes Play a Critical Role in the Fibrogenesis in Myeloproliferative Neoplasms and Can be Used As a Therapeutic Target to Ameliorate Fibrosis
中文标题:CD38高表达的单核细胞在骨髓增殖性肿瘤纤维化中起关键作用,并可作为改善纤维化的治疗靶点
汇报人:Bing Li [中国医学科学院血液病医院(中国医学科学院血液学研究所)]
汇报时间:Monday, December 9, 2024: 3:30 PM
汇报地点:Seaport Ballroom EFGH (Manchester Grand Hyatt San Diego
28
摘要号:904
标题:CD33 Antibody-Modified Nanoparticles Encapsulated IL-15 Induce ISG15 to Promote MHC I Expression in Leukemia Cells Via Innate Immunity Pathway Inducing Graft-Versus-Leukemia without Aggravating Graft-Versus-Host Disease
中文标题:包裹IL-15的CD33抗体修饰的纳米粒子通过先天免疫途径诱导ISG15促进白血病细胞中MHC I的表达,诱导移植物抗白血病,而不会加重移植物抗宿主病
汇报人:Ruowen Wei(华中科技大学同济医学院附属协和医院血液研究所)
汇报时间:Monday, December 9, 2024: 3:30 PM
汇报地点:Room 6B (San Diego Convention Center)
29
摘要号:921
标题:A Novel Generation of Anti-CD7 Universal CAR-T Therapy for Patients with Relapsed or Refractory CD7 Positive T-ALL/Lbl: A Phase I Clinical Trial
中文标题:新一代抗CD7通用CAR-T疗法治疗复发或难治性CD7阳性T细胞急性淋巴细胞白血病/淋巴母细胞淋巴瘤患者的I期临床试验
汇报人:胡永仙(浙江大学医学中心良渚实验室)
汇报时间:Monday, December 9, 2024: 3:15 PM
汇报地点:Hall B (San Diego Convention Center)
30
摘要号:923
中文标题:一项前瞻性研究者发起的BCMA/CD19双靶点CAR T细胞疗法治疗复发/难治性多发性骨髓瘤(包括髓外病变患者)的I/II期研究
汇报人:Hua Jiang(同济大学医学院上海第四人民医院)
汇报时间:Monday, December 9, 2024: 3:45 PM
汇报地点:Hall B (San Diego Convention Center)
31
摘要号:956
中文标题:一种高选择性和口服生物可利用的CK1α分子胶降解剂靶向B细胞淋巴瘤细胞
汇报人:Ran Kong(山东大学山东省医院血液科)
汇报时间:Monday, December 9, 2024: 4:45 PM
汇报地点:Ballroom 20CD (San Diego Convention Center)
32
摘要号:958
标题:KPT-330 Combined with Radiation Therapy: Effective Central Nervous System Lymphoma Treatment with Reduced Neurotoxicity
中文标题:KPT-330联合放疗有效治疗中枢神经系统淋巴瘤并降低神经毒性
汇报人:Bingzong Li(苏州大学附属第二医院)
汇报时间:Monday, December 9, 2024: 5:15 PM
汇报地点:Ballroom 20CD (San Diego Convention Center)
33
摘要号:960
汇报人:Hui Yu(北京大学肿瘤医院)
汇报时间:Monday, December 9, 2024: 5:45 PM
汇报地点:Ballroom 20CD (San Diego Convention Center)
34
摘要号:964
标题:CD7 CAR T-Cell Therapy in Relapsed or Refractory T-Cell Acute Lymphoblastic Leukemia: A Retrospective Study
中文标题:CD7 CAR-T细胞疗法治疗复发或难治性T细胞急性淋巴细胞白血病的回顾性研究
汇报人:潘静(北京高博医院)
汇报时间:Monday, December 9, 2024: 5:15 PM
汇报地点:Marriott Grand Ballroom 5-6 (Marriott Marquis San Diego Marina)
35
摘要号:971
标题:Venetoclax and Decitabine Compared with Standard Intensive Chemotherapy As Induction Therapy in Newly Diagnosed Acute Myeloid Leukemia: Updated Results of a Multicenter, Randomized, Phase 2b Trial
中文标题:维奈托克联合地西他滨与标准强化化疗作为新诊断急性髓系白血病诱导治疗的比较:一项多中心、随机、IIb期试验的更新结果
汇报人:Jing Lu(苏州大学附属第一医院)
汇报时间:Monday, December 9, 2024: 5:30 PM
汇报地点:Grand Hall B (Manchester Grand Hyatt San Diego)
36
摘要号:972
中文标题:首次完全缓解期急性髓系白血病患者首次巩固治疗中高剂量阿糖胞苷联合伊达比星对比高剂量阿糖胞苷:一项开放标签、多中心、随机、III期试验
汇报人:Zinan Feng(南方医科大学南方医院血液科)
汇报时间:Monday, December 9, 2024: 5:45 PM
汇报地点:Grand Hall B (Manchester Grand Hyatt San Diego)
37
摘要号:977
中文标题:Prausnitzii粪杆菌对NKTCL的发展具有保护作用
汇报人:Zhuangzhuang Shi(郑州大学第一附属医院)
汇报时间:Monday, December 9, 2024: 5:30 PM
汇报地点:Marriott Grand Ballroom 11-13 (Marriott Marquis San Diego Marina)
38
|
历史震惊你 · 解密丨年轻时的慈禧,到底啥样儿? 8 年前 |
|
军情战评 · 美媒:中国海军继续扩张 是美国下一个威胁? 7 年前 |
|
魔鬼心理学 · ◁女人的一生,最容易“毁”在这一点 7 年前 |
|
彩虹兔 · 四月“泰”好玩获奖名单 7 年前 |
|
72变 · 机不可失,湿不再来 — 如何应对梅雨季? 7 年前 |